表紙
市場調査レポート

中国のテルミサルタン市場の分析

Investigation Report on China Telmisartan Market, 2010-2019

発行 China Research and Intelligence 商品コード 296863
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
中国のテルミサルタン市場の分析 Investigation Report on China Telmisartan Market, 2010-2019
出版日: 2015年06月18日 ページ情報: 英文 30 Pages
概要

テルミサルタン(Telmisartan)はBoehringer Ingelheimによって開発された降圧剤で、1999年に「Micardis」というブランド名で米国で上市されました。中国では現在、3億人(成人の3人に1人)を超える高血圧患者が存在します。しかし、自分の症状を適切に理解している患者は全体の40%以下で、さらにそのうちの1/4だけが適切な管理を実行できている状態です。2000年の終わりに中国に上陸したテルミサルタンは急速に売り上げを伸ばし、同市場は2005〜2014年に年平均(CAGR)35.8%もの成長を遂げ、その後も10%程度の成長率を維持しています。

当レポートでは、中国におけるテルミサルタン市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果をお届けします。

第1章 テルミサルタンの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のテルミサルタン市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 テルミサルタンの売上高の分析

  • 売上高
    • 全体
    • 地域別
  • 販売量
    • 全体
    • 地域別

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 テルミサルタンの病院向け基準価格(企業別)

  • Boehringer Ingelheim
  • Beijing Wansheng Pharmaceutical Co., Ltd
  • China Resources Double Crane Pharmaceutical Co., Ltd
  • Yichang Changjiang Pharmaceutical Co., Ltd.
  • Wanbang Biopharmaceuticals (Trade Name: Bang Tan)
  • Hainan Selection Pharmaceutical Co., Ltd.
  • Dawnrays Pharmaceutical Limited

第7章 主要メーカーの分析

  • Boehringer Ingelheim
  • China Resources Double Crane Pharmaceutical Co., Ltd
  • Yichang Changjiang Pharmaceutical Co., Ltd.
  • Wanbang Biopharmaceutical Co., Ltd.
  • Hainan Selection Pharmaceutical Co., Ltd.

第8章 中国のテルミサルタン市場の将来展望

  • 市場規模の予測
  • 市場パターンの予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1506218

The number of hypertension patients in China is estimated to surpass 300 million with one in three adults suffering from it.

Out of all the dyazides, angiotension receptor blocker (ARB) is among a new generation which grows fast. Ever since the appearance of losartan which has been first applied in the clinic, 8 kinds of similar drugs have come out for sale and there are also 5 kinds of generic drugs in China. In recent years, telmisartan could be said as the fastest-growing kind of dyazide.

First developed by Boehringer-Ingelheim (Germany) and first marketed in the US in 1999 under the trade name of Micardis, telmisartan is an oral drug for the treatment of essential hypertension which should be taken once a day. It was marketed by Boehringer-Ingelheim under the trade name of Micardis and by Glaxo Wellcome plc under the trade name of Pritor in Germany in the same year. Telmisartan entered the Philippines in Dec. 1999 and Australia, Belgium, Britain in 2000. In 2013, its sales value surpassed USD 3 billion in the world. The patent of telmisartan expired in 2014.

The active pharmaceutical ingredients (APIs) and preparations of telmisartan were introduced by Boehringer-Ingelheim into China for sales at the end of 2000. After entering China, telmisartan grows fast with annual sales value rising from less than CNY 13 million in 2005 to CNY 200 million in 2014 and CAGR during this period reaching up to 35.8% despite a slight fall in 2014. Currently, telmisartan in the Chinese market mainly come from the following companies: Boehringer-Ingelheim (Germany), China Resources Double Crane Pharmaceutical Co., Ltd, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals and Hainan Selection Pharmaceutical Co., Ltd, among which Boehringer-Ingelheim (Germany) has the largest market share of over 80%, sales value in 2014 reaching up to CNY 167 million.

The market size of telmisartan in China is estimated to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of telmisartan in China
  • competitive landscape of telmisartan in Chinese market
  • price of telmisartan made by different manufactures in China
  • market outlook of telmisartan in China

The author suggests the following groups of people purchase this report:

  • manufacturers of dyazide
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Telmisartan

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Telmisartan in China

  • 2.1. Patent and Approval Status of Telmisartan in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Telmisartan in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Telmisartan in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Telmisartan in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Telmisartan in Chinese Hospitals in 2014

  • 6.1. Boehringer-Ingelheim (Germany) (Trade Name: Micardis)
  • 6.2. Beijing Wansheng Pharmaceutical Co., Ltd (Trade Name: Shu Ni Ya)
  • 6.3. China Resources Double Crane Pharmaceutical Co., Ltd (Trade Name: Su He)
  • 6.4. Yichang Changjiang Pharmaceutical Co., Ltd (Trade Name: Ou Mei Ning)
  • 6.5. Wanbang Biopharmaceuticals (Trade Name: Bang Tan)
  • 6.6. Hainan Selection Pharmaceutical Co., Ltd (Trade Name: Li Wen)
  • 6.7. Dawnrays Pharmaceutical Limited (Trade Name: An Nei Qiang)

7. Major Manufacturers of Telmisartan in Chinese Market, 2010-2014

  • 7.1. Boehringer-Ingelheim
  • 7.2. China Resources Double Crane Pharmaceutical Co., Ltd
  • 7.3. Yichang Changjiang Pharmaceutical Co., Ltd
  • 7.4. Wanbang Biopharmaceuticals
  • 7.5. Hainan Selection Pharmaceutical Co., Ltd

8. Market Outlook of Telmisartan in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Telmisartan in China
  • Chart Approval Information of Telmisartan in China
  • Chart Sales Status of Telmisartan in China
  • Chart Sales Value of Telmisartan in China, 2010-2014
  • Chart Sales Value of Telmisartan in Some Regions in China, 2010-2014
  • Chart Sales Volume of Telmisartan in China, 2010-2014
  • Chart Sales Volume of Telmisartan in Some Regions in China, 2010-2014
  • Chart Market Share of TOP4 Manufacturers of Telmisartan for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by Boehringer-Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by Yichang Changjiang in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by China Resources Double Crane in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by Hainan Selection in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Capsules in China, 2010-2014
  • Chart Price of Telmisartan Made by Boehringer-Ingelheim (Germany) in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Beijing Wansheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by China Resources Double Crane Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Yichang Changjiang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Wanbang Biopharmaceuticals in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Hainan Selection Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Dawnrays Pharmaceutical Limited in Some Chinese Cities in 2014
Back to Top